Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 46

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

A Randomized Controlled Trial of Intravenous N-Acetylcysteine in the Management of Anti-tuberculosis Drug–Induced Liver Injury

Moosa, Muhammed Shiraz, Maartens, Gary, Gunter, Hannah, Allie, Shaazia, Chughlay, Mohamed F, Setshedi, Mashiko, Wasserman, Sean, Stead, David F, Hickman, Nicole, Stewart, Annemie, Sonderup, Mark, Spearman, Catherine Wendy, Cohen, Karen·2021·Clinical Infectious Diseases

Abstract

Background: Liver injury is a common complication of anti-tuberculosis therapy. N-acetylcysteine (NAC) used in patients with paracetamol toxicity with limited evidence of benefit in liver injury due to other causes. Methods: We conducted a randomized, double-blind, placebo-controlled trial to assess the efficacy of intravenous NAC in hospitalized adult patients with anti-tuberculosis drug–induced liver injury (AT-DILI). The primary endpoint was time for serum alanine aminotransferase (ALT) to fall below 100 U/L. Secondary endpoints included length of hospital stay, in-hospital mortality, and adverse events. Results: Fifty-three participants were randomized to NAC and 49 to placebo. Mean age was 38 (SD±10) years, 58 (57%) were female, 89 (87%) were HIV positive. Median (IQR) serum ALT and bilirubin at presentation were 462 (266–790) U/L and 56 (25–100) μmol/L, respectively. Median time to ALT <100 U/L was 7.5 (6–11) days in the NAC arm and 8 (5–13) days in the placebo arm. Median time to hospital discharge was shorter in the NAC arm (9 [6–15] days) than in the placebo arm (18 [10–25] days) (HR, 1.73; 95% CI, 1.13–2.65). Mortality was 14% overall and did not differ by study arm. The study infusion was stopped early due to an adverse reaction in 5 participants receiving NAC (nausea and vomiting [3], anaphylaxis [1], pain at drip site [1]). Conclusions: NAC did not shorten time to ALT <100 U/L in participants with AT-DILI, but significantly reduced length of hospital stay. NAC should be considered in management of AT-DILI. Clinical Trials Registration: South African National Clinical Trials Registry (SANCTR: DOH-27-0414-4719).

Overview

Integrity signals

Registry

Crossref · 10.1093/cid/ciaa1255

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 2 references

Research works printed but not linked: 26

  1. Tostmann, 2008, Antituberculosis drug-induced hepatotoxicity: concise up-to-date review, J Gastroenterol Hepatol, 23, 192, 10.1111/j.1440-1746.2007.05207.x · DOI · Paper page
  2. Abbara, 2017, Drug-induced liver injury from antituberculous treatment: a retrospective study from a large TB centre in the UK, BMC Infect Dis, 17, 231, 10.1186/s12879-017-2330-z · DOI · Paper page
  3. Devarbhavi, 2013, Outcome and determinants of mortality in 269 patients with combination anti-tuberculosis drug-induced liver injury, J Gastroenterol Hepatol, 28, 161, 10.1111/j.1440-1746.2012.07279.x · DOI · Paper page
  4. Schutz, 2012, Burden of antituberculosis and antiretroviral drug-induced liver injury at a secondary hospital in South Africa, S Afr Med J, 102, 506, 10.7196/SAMJ.5650 · DOI
  5. Saukkonen, 2006, An official ATS statement: hepatotoxicity of antituberculosis therapy, Am J Respir Crit Care Med, 174, 935, 10.1164/rccm.200510-1666ST · DOI · Paper page
  6. Rank, 2000, N-acetylcysteine increases liver blood flow and improves liver function in septic shock patients: results of a prospective, randomized, double-blind study, Crit Care Med, 28, 3799, 10.1097/00003246-200012000-00006 · DOI · Paper page
  7. Shi, 2005, A multi-center clinical study of N-acetylcysteine on chronic hepatitis B, Zhonghua Gan Zang Bing Za Zhi, 13, 20
  8. Darweesh, 2017, Effect of N-acetylcysteine on mortality and liver transplantation rate in non-acetaminophen-induced acute liver failure: a multicenter study, Clin Drug Investig, 37, 473, 10.1007/s40261-017-0505-4 · DOI
  9. Lee, 2009, Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure, Gastroenterology, 137, 856, 10.1053/j.gastro.2009.06.006 · DOI · Paper page
  10. Chughlay, 2016, N-acetylcysteine for non-paracetamol drug-induced liver injury: a systematic review, Br J Clin Pharmacol, 81, 1021, 10.1111/bcp.12880 · DOI
  11. Attri, 2000, Isoniazid- and rifampicin-induced oxidative hepatic injury—protection by N-acetylcysteine, Hum Exp Toxicol, 19, 517, 10.1191/096032700674230830 · DOI
  12. Singh, 2012, Protective effect of curcumin, silymarin and N-acetylcysteine on antitubercular drug-induced hepatotoxicity assessed in an in vitro model, Hum Exp Toxicol, 31, 788, 10.1177/0960327111433901 · DOI
  13. Baniasadi, 2010, Protective effect of N-acetylcysteine on antituberculosis drug-induced hepatotoxicity, Eur J Gastroenterol Hepatol, 22, 1235, 10.1097/MEG.0b013e32833aa11b · DOI
  14. Polson, 2005, AASLD position paper: the management of acute liver failure, Hepatology, 41, 1179, 10.1002/hep.20703 · DOI · Paper page
  15. Vilstrup, 2014, Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver, Hepatology, 60, 715, 10.1002/hep.27210 · DOI · Paper page
  16. Sharma Surendra, 2010, Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment–induced hepatotoxicity, Clin Infect Dis, 50, 833, 10.1086/650576 · DOI
  17. World Medical Association, 2013, World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects, JAMA, 310, 2191, 10.1001/jama.2013.281053 · DOI · Paper page
  18. Metushi, 2016, Mechanism of isoniazid-induced hepatotoxicity: then and now, Br J Clin Pharmacol, 81, 1030, 10.1111/bcp.12885 · DOI · Paper page
  19. McGill, 2016, The past and present of serum aminotransferases and the future of liver injury biomarkers, EXCLI J, 15, 817
  20. Lindblom, 2007, Isoforms of alanine aminotransferases in human tissues and serum—differential tissue expression using novel antibodies, Arch Biochem Biophys, 466, 66, 10.1016/j.abb.2007.07.023 · DOI
  21. Sanjay, 2017, Role of miRNA and its potential as a novel diagnostic biomarker in drug-induced liver injury, Eur J Clin Pharmacol, 73, 399, 10.1007/s00228-016-2183-1 · DOI
  22. Thulin, 2014, Keratin-18 and microRNA-122 complement alanine aminotransferase as novel safety biomarkers for drug-induced liver injury in two human cohorts, Liver Int, 34, 367, 10.1111/liv.12322 · DOI · Paper page
  23. Li, 2014, MicroRNAs in drug-induced liver injury, J Clin Transl Hepatol, 2, 162
  24. Hummelen, 2010, Micronutrients, N-acetyl cysteine, probiotics and prebiotics, a review of effectiveness in reducing HIV progression, Nutrients, 2, 626, 10.3390/nu2060626 · DOI
  25. Amaral, 2016, N-acetyl-cysteine exhibits potent anti-mycobacterial activity in addition to its known anti-oxidative functions, BMC Microbiol, 16, 251, 10.1186/s12866-016-0872-7 · DOI
  26. Teskey, 2018, The synergistic effects of the glutathione precursor, NAC and first-line antibiotics in the granulomatous response against Mycobacterium tuberculosis, Front Immunol, 9, 2069, 10.3389/fimmu.2018.02069 · DOI

Cited by

See all 46

Metadata

Authors
Moosa, M. S., Maartens, G., Gunter, H., Allie, S., Chughlay, M. F., Setshedi, M., Wasserman, S., Stead, D. F., Hickman, N., Stewart, A., Sonderup, M., Spearman, C. W., & Cohen, K.
Affiliations
  • Department of Medicine, University of Cape Town, Cape Town, South Africa
  • Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa
  • Division of Gastroenterology, Department of Medicine, University of Cape Town, Cape Town, South Africa
  • Division of Infectious Diseases and HIV Medicine, Department of Medicine, University of Cape Town, Cape Town, South Africa
  • Clinical Research Centre, University of Cape Town, Cape Town, South Africa
  • Division of Hepatology, Department of Medicine, University of Cape Town, Cape Town, South Africa
Venue
Clinical Infectious Diseases
Published
2020-08-26
Volume
73
Issue
9
Pages
e3377-e3383
ISSN
  • 1058-4838
  • 1537-6591
Cited by
46
References
2
Language
en
Funders
South African Medical Research Council

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Randomized Controlled Trial of Intravenous N-Acetylcysteine in the Management of Anti-tuberculosis Drug–Induced Liver Injury. https://app.cochat.ai/papers/10.1093/cid/ciaa1255
The paper
Moosa, M. S., Maartens, G., Gunter, H., Allie, S., Chughlay, M. F., Setshedi, M., Wasserman, S., Stead, D. F., Hickman, N., Stewart, A., Sonderup, M., Spearman, C. W., & Cohen, K. (2021). A Randomized Controlled Trial of Intravenous N-Acetylcysteine in the Management of Anti-tuberculosis Drug–Induced Liver Injury. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciaa1255

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.